News

Nanocyclix portfolio - R&D pipeline
Biotech
23/11/2021

Biotech Show Case: looking for partners to pursue the development of our Nanocyclix® technology products together!

Meet Dr. Jan Hoflack during Biotech ShowCase to explore our products pipeline using our technological module Nanocyclix®.

A molecule in the active site of RIPK2
Biotech
04/11/2021

ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease

Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia

EHDEN - The European Health Data & Evidence Network - Oncodesign
Corporate
A.I
28/10/2021

Oncodesign: EHDEN Certified SME

EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline.

Karine Lignel | Senior Executive Vice President - Group Chief Development Officer - Oncodesign
Corporate
Financial
25/10/2021

Oncodesign has appointed Karine Lignel as Group Chief Development Officer

Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.

Oncodesign x TiumBio signed a collaboration agreement | Fibrosis
Biotech
21/10/2021

Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates

Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.

20/10/2021

[WEBINARS] Pharmaco-imaging, COVID-19, Microbiome…

[Webinars] Radiopharmaceutics, COVID-19, Microbiome… join us this fall during a webinar

Service
19/10/2021

[CONGRESS] Discovery UK: 26 – 27 October 2021

Oncodesign will be at the in-person event by Oxford Global in London, Discovery UK.

Financial
16/09/2021

Oncodesign announces its results for the first half of 2021

Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.

Corporate
Financial
05/07/2021

Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors

Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.

Corporate
02/07/2021

Find out how we built our logo!

Oncodesign Find out how we built our logo! trajectory DNA innovation...green and bleue pharma colors Find out how we built our logo!

Corporate
01/07/2021

Brand new logo for Oncodesign

Brand new logo for Oncodesign. New graphic identity with evolutive look & feel approach... First element of our new logo.

Biotech
Financial
24/06/2021

Oncodesign provides an update on its progress on RIPK2

[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.